UBS Group’s BioSpecifics Technologies Corp. BSTC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-3,005
Closed -$159K 9099
2020
Q3
$159K Sell
3,005
-750
-20% -$46.3K ﹤0.01% 4927
2020
Q2
$230K Sell
3,755
-1,940
-34% -$112K ﹤0.01% 4710
2020
Q1
$322K Sell
5,695
-12,148
-68% -$692K ﹤0.01% 4341
2019
Q4
$1.02M Buy
17,843
+1,900
+12% +$101K ﹤0.01% 4199
2019
Q3
$853K Buy
15,943
+4,033
+34% +$235K ﹤0.01% 4097
2019
Q2
$711K Buy
11,910
+3,325
+39% +$209K ﹤0.01% 4019
2019
Q1
$535K Buy
8,585
+4,800
+127% +$318K ﹤0.01% 4022
2018
Q4
$229K Buy
3,785
+507
+15% +$30.3K ﹤0.01% 4860
2018
Q3
$192K Buy
3,278
+633
+24% +$32.3K ﹤0.01% 5099
2018
Q2
$119K Sell
2,645
-1,789
-40% -$76.9K ﹤0.01% 5319
2018
Q1
$197K Sell
4,434
-1,208
-21% -$50.7K ﹤0.01% 4793
2017
Q4
$244K Sell
5,642
-722
-11% -$32.5K ﹤0.01% 4781
2017
Q3
$296K Sell
6,364
-597
-9% -$28.6K ﹤0.01% 4577
2017
Q2
$344K Buy
6,961
+757
+12% +$39.7K ﹤0.01% 4390
2017
Q1
$340K Sell
6,204
-761
-11% -$40.3K ﹤0.01% 4299
2016
Q4
$388K Buy
6,965
+1,207
+21% +$58K ﹤0.01% 4304
2016
Q3
$263K Buy
5,758
+196
+4% +$7.87K ﹤0.01% 4349
2016
Q2
$222K Buy
5,562
+219
+4% +$8.02K ﹤0.01% 4483
2016
Q1
$186K Buy
5,343
+841
+19% +$30.9K ﹤0.01% 4537
2015
Q4
$194K Sell
4,502
-889
-16% -$44.5K ﹤0.01% 4695
2015
Q3
$234K Buy
5,391
+2,882
+115% +$156K ﹤0.01% 4503
2015
Q2
$129K Buy
2,509
+2,350
+1,478% +$100K ﹤0.01% 5214
2015
Q1
$6K Sell
159
-76
-32% -$2.98K ﹤0.01% 8036
2014
Q4
$9K Buy
+235
New +$8.97K ﹤0.01% 8513

Other funds holding BSTC

UBS Group's BSTC Position: Q4 2020 in Review

UBS Group sold out of BioSpecifics Technologies Corp. (BSTC) in Q4 2020, closing a stake of 3,005 shares — an estimated $159K sold.

UBS Group first reported a position in BSTC in Q4 2014 and held it in 24 quarters. The position peaked at $1.02M in Q4 2019. 1 fund tracked by Wall St. Rank holds BSTC as of Q4 2020.

  • UBS Group reported no remaining BioSpecifics Technologies Corp. position as of Q4 2020 after selling out during the quarter.
  • UBS Group sold 3,005 BioSpecifics Technologies Corp. shares in Q4 2020, an estimated $159K.
  • UBS Group first reported a position in BioSpecifics Technologies Corp. in Q4 2014 and held it in 24 quarters.
  • UBS Group's BioSpecifics Technologies Corp. position peaked at $1.02M in Q4 2019.
  • 1 fund tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q4 2020.

Based on UBS Group's 13F filing for Q4 2020, filed 11 Feb 2021.